Dyne Therapeutics (DYN) shares were up 1.7% in early trading Thursday after the company reported a Q4 net loss of $0.88 per diluted share, compared with a $1.09 loss a year earlier.
Analysts polled by FactSet expected a $0.94 loss.
The company did not report revenue for the quarter ended Dec. 31.
The company said it had $642.3 million in cash, cash equivalents and marketable securities as of Dec. 31, which together with about $140.6 million in net proceeds from a recent at-the-market offering is expected to fund operations at least into H2 of 2026.
Price: 14.03, Change: +0.24, Percent Change: +1.74
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。